相关实验视频
Updated: Jan 16, 2026

16:15
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
21.6K
酶转化O脏允许在人类死者模型中不经过急性排斥的情况下进行ABO不兼容的移植
Jun Zeng1,2, Ming Ma1,2,3, Ze Tao3,4,5
1Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Nature biomedical engineering
|October 3, 2025
概括
一种以捐赠者为中心的新方法将A型脏转化为O型脏,降低了ABO不兼容脏移植中排斥风险. 这种器官工程策略提高了移植的可访问性和公平性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 移植免疫学 移植免疫学
- 器官工程 器官工程是指器官工程.
背景情况:
- 对ABO不兼容的移植对于器官供应至关重要,但由于当前的接受者脱敏协议,它面临着挑战.
- 基于等离子酶的协议增加了感染,出血风险和医疗费用.
- 对于ABO不兼容的脏移植,需要更安全,更容易获得的策略.
研究的目的:
- 开发和评估一个以捐赠者为中心的无敏化协议,用于ABO不兼容的移植.
- 评估酶性从捐赠脏中去除A抗原的疗效.
- 调查改善器官分配和患者治疗结果的潜力.
主要方法:
- 开发了一种以捐赠者为中心的协议,用于将A型脏转化为O型脏,在低温输液过程中使用酶性A抗原去除.
- 验证了ex vivo模型的抗体介导损伤的缺失.
- 将一个酶转化O型移植到一个具有高抗A抗体标位的O型受体中.
- 通过班夫分数和单细胞测序监测移植耐受性,抗体中介排斥,A抗原再生和免疫反应.
主要成果:
- 活体模型显示没有抗体介导的损伤.
- 移植脏没有显示过敏排斥,并且在2天内耐受良好.
- 抗体介导的病变和补体沉积在第3天出现,与A抗原再生相吻合.
- 观察到与适应相关的基因的表达升高,这表明对耐受性的潜力.
结论:
- 捐赠脏的酶转化为ABO不兼容移植提供了一个有前途的以捐赠者为中心的战略.
- A抗原再生需要进一步的研究,以确保长期的移植存活.
- 这种方法有可能扩大对移植的准入,并改善器官分配的公平性.
相关概念视频
Kidney Transplant I: Introduction
340
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
340
Kidney Transplant II: Surgical Procedure
307
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
307

